Perthera

After seeing record numbers of people at our poster talk and having our work featured in ASCO GI’s Poster Walk we would like to thank everyone who contributed and participated in the session!  So many people were at the talk for  “Validation of the PDACai signature in predicting relative benefit from frontline FOLFIRINOX (FFX) and gemcitabine/nab-paclitaxel (GA) for patients (pts) with metastatic pancreatic cancer (mPDAC)” that we completely ran out of copies of the poster! If you missed snagging one onsite, here’s a link to the original press release and poster abstract: Read the press release to get the full details and to understand the impact of this trailblazing discovery. https://lnkd.in/ebq647Cz Review the poster abstract and download a PDF of the poster at:  https://lnkd.in/e_VVUKvh Study collaborators include: Pancreatic Cancer Action Network, Johns Hopkins Medicine, Oregon Health & Science University, Cedars-Sinai, George Mason University The original press release contains quotes from: Anna Bergen, Flavio Rocha, Emanuel Petricoin and Donna Tuths #StandUpToCancer #BeatCancer #PancreaticCancer #PanCan #hellopancreas #folfirinox #chemo #gemcitabine #Perthera #TherapeuticIntelligence #AI #AdvancedDecisionSupport

ASCO GI 25 Participants in the Pancreatic Cancer - Advanced/Metastatic Disease Track: Be sure to visit the poster session for the “Validation of the PDACai signature in predicting relative benefit from frontline FOLFIRINOX (FFX) and gemcitabine/nab-paclitaxel (GA) for patients (pts) with metastatic pancreatic cancer (mPDAC)”.  We look forward to seeing you at ASCO GI 25! Read the press release to get the full details and to understand the impact of this trailblazing discovery. https://lnkd.in/dn5Jn5Si Study collaborators include: Pancreatic Cancer Action Network, Johns Hopkins Medicine, Oregon Health & Science University, Cedars-Sinai and George Mason University The press release above contains quotes from: Anna Berkenblit, Flavio Rocha, Emanuel Petricoin and Donna Tuths. Poster presenters include Michael Pishvaian and Edik Blais

BREAKING NEWS: A major innovation in Pancreatic Cancer Care. Perthera announces the discovery of the world's first AI-driven Chemotherapy predictor for the frontline treatment of pancreatic adenocarcinoma (PDAC), a cancer that has a five-year survival rate of less than 8% globally.  We are announcing a validated artificial intelligence signature (PDACai) designed to predict front-line chemotherapy effectiveness for newly diagnosed patients. It will be available for ordering physicians in February 2025. Prior to PDACai, there was no way for an oncologist to know which of the two current most frequently used treatments a patient would most likely respond to without trialing the patient on each of these drug regimens, losing critical time and impacting overall survival.     PDACai analyzes patient genomic, clinical, epidemiological, treatment and outcome data to predict the relative effectiveness of the two most common frontline chemotherapy regimens for PDAC —FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GA). The platform delivers actionable predictions to help physicians optimize this critical frontline treatment sequencing and improve outcomes for individual patients. Read the press release to get the full details and to understand the impact of this trailblazing discovery: https://lnkd.in/eXWDxcNR Access an overview poster of the research study here: https://lnkd.in/eNmmTDhj Study collaborators include: Pancreatic Cancer Action Network, Johns Hopkins Medicine, Oregon Health & Science University, Cedars-Sinai, George Mason University The press release contains quotes from: Anna Berkenblit, Flavio Rocha, Emanuel Petricoin and Donna Tuths #StandUpToCancer #BeatCancer #PancreaticCancer #PanCan #hellopancreas #folfirinox #chemo #gemcitabine #Perthera #TherapeuticIntelligence #AI #AdvancedDecisionSupport

Oncologists use our report to identify the optimal therapy for their patients and to drive better outcomes. The newly launched Perthera Report 4.0 transforms complex molecular and multi-omic data into ranked, actionable treatment options. Click this link to learn how the report can save you time and improve patient outcomes: https://lnkd.in/eMcN4kVA Click this link to read the full press release https://lnkd.in/euKYwzM5 #StandUpToCancer #BeatCancer #Perthera #TherapeuticIntelligence #AI #AdvancedDecisionSupport Donna Tuths

We are excited to announce that Perthera has unveiled groundbreaking research that finds survival differences in lung vs liver metastasis. In a recent study we highlight a difference of up to 8.2 months in advanced pancreatic cancer based on location of the metastasis.  Essentially, survival outcomes are longer if the cancer metastases to the lung vs the liver.   Read the full press release here: https://lnkd.in/duWhzNb5 Access a poster for the study here: https://lnkd.in/dnj6e8AE Study collaborators include: Cedars-Sinai, Johns Hopkins Medicine, UNC Lineberger Comprehensive Cancer Center and Arizona State University Support was provided by the Pancreatic Cancer Action Network #StandUpToCancer #BeatCancer  #PancreaticCancer #PancChat #PancreaticCancerAwareness #Perthera #TherapeuticIntelligence #AI #AdvancedDecisionSupport Emanuel Petricoin, Donna Tuths

JUST ANNOUNCED:  Landmark study shows multi-omic testing’s role in improving outcomes for metastatic breast cancer. After collaborating with leading researchers from George Mason University and The Side-Out Foundation, we are thrilled to share a groundbreaking study published in the British Journal of Cancer emphasizing the transformative impact of multi-omic molecular testing in guiding treatment for metastatic breast cancer. Read the full press release here: https://lnkd.in/e5yCSfpC Access the study here: https://lnkd.in/en3mQdHr #StandUpToCancer#BeatCancer  #BCSM #bccww #Breastcancer #busylivingwithmets #georgemasonuniversity #GMU #thesideoutfoundation #Perthera #TherapeuticIntelligence #Perthera#AI #AdvanceDecisionSupport Emanuel Petricoin, Rick Dunetz,George Mason University - College of Science, The Side-Out Foundation

We are excited to welcome Brant Adornato to our team! He leads our growth & transformation initiatives as we scale our core business & commercial processes.   To learn more about Brant's extensive experience in commercial launches and business operations at leading healthcare organizations, visit his LinkedIn profile. Brant A. #TherapeuticIntelligence #Perthera #AI #AdvanceDecisionSupport #StandUpToCancer #BeatCancer

Perthera just released a new version of our patented Virtual Molecular Tumor Board application, vMTB 4.0!  With this update, we are further accelerating the AI learning component of Perthera’s Therapeutic Intelligence Engine. Read our detailed announcement to find out how this release further enhances the precision of our ranking engine, to ensure our technology delivers the most advanced decision support available to clinicians treating cancer patients! https://lnkd.in/eAZ5zkgb #TherapeuticIntelligence #Perthera #AI #AdvanceDecisionSupport #StandUpToCancer #BeatCancer

Join our Co-Founder Dr. Emanuel Petricoin's session at the Advancing Precision Medicine Conference in Philadelphia: PRESENTATION Saturday, November 2 | 9:50 AM EST Implementation of a CLIA-based Reverse Phase Protein Array Assay for Precision Oncology Applications: Proteomics and Phosphoproteomics at the Bedside (CME Eligible) Learn More: https://lnkd.in/gBM424UK #perthera #precisiononcology #APM Emanuel Petricoin

We’re delighted to present our new CMO! https://lnkd.in/gZdGbGc4 She’s an industry veteran who’s excited about driving growth for Perthera, a pioneer in Precision Oncology Decision Support.